Effects of trazodone and fluoxetine in the treatment of major depression: Therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine

Journal of Clinical Psychopharmacology

Volumn 17, Issue 5, 1997, Pages 358-364

  Maes, Michael ^a,b   Westenberg, Herman ^c   Vandoolaeghe, Eric ^a   Demedts, Paul ^d   Wauters, Annick ^d   Neels, Hugo ^d   Meltzer, Herbert Y ^b  

^a Clinical Research Center for Mental Health of Antwerp   (Belgium)

^b VANDERBILT UNIVERSITY   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Laboratory of Clinical Biology   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ANTIDEPRESSANT AGENT; DRUG METABOLITE; FLUOXETINE; PINDOLOL; PLACEBO; SEROTONIN 1C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INTERACTION; HAMILTON SCALE; HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PINDOLOL; PIPERAZINES; TRAZODONE; TREATMENT OUTCOME;

EID: 0030770870     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199710000-00004     Document Type: Article

References (56)

1. Maes M, Meltzer HYM. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 933-44.
2. Fuller RW. Minireview. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 1994;55:163-7.
3. Blier P, de Montigny G, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: pre-clinical evidence. J Clin Psychiatry 1990;51:14-20.
4. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol and fluoxetine in major depression. J Affect Disord 1996;17:201-10.
5. Hyttel J. Citalopram-pharmacologic profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:277-95.
6. Chaput Y, de Montigny C, Blier P. Pre- and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: an in vivo electrophysiological study in the rat. Neuropsychopharmacology 1991;5:219-27.
7. Briley M, Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol 1993;16:387-400.
8. Dowdall M, de Montigny C. Pre- and postsynaptic effects of trazodone on serotonin neurotransmission: single cell studies in the rat [abstract]. Psychotherapeutic Drugs 1984:10:17.
9. Artigas F. Pindolol, 5-hydroxytryptamine, and antidepressant augmentation. Arch Gen Psychiatry 1995;52:969-71.
10. 1A receptors. Neurochem Res 1996;21:557-62.
11. 1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behav Brain Res 1996;73:281-3.
12. Marek GJ, McDougle CJ, Price LH, Seiden LS. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology 1992;109:2-11.
13. Sulser F. Mode of action of antidepressant drugs. J Clin Psychiatry 1983;44:14-20.
14. Smith TM, Suckow RF. Trazodone and m-chlorophenylpiperazine: concentration in brain and receptor activity in regions in the brain associated with anxiety. Neuropharmacology 1985;24: 1067-71.
15. Caccia S, Ballabio M, Samanin R, Zanini MG, Garratini S. m-Chlorophenyl-piperazine, a central 5-hydroxytryptamine agonist is a metabolite of trazodone. J Pharm Pharmacol 1981;33:477-8.
16. 1B receptor ligands exist? Arch Pharm (Weinheim) 1989;339:675-83.
17. 1B receptor subtypes in rat frontal cortex. J Pharmacol Exp Ther 1984;231:480-7.
18. 1C receptors. J Pharmacol Exp Ther 1987;242:552-7.
19. Caccia S, Fong MH, Garratini S, Zanini MG. Plasma concentrations of trazodone and 1-(3-chlorophenyl)piperazine in man after a single oral dose of trazodone. J Pharm Pharmacol 1982;34: 605-6.
20. Fuller RW. 1-Phenylpiperazines and related compounds as centrally acting serotonin agonists. In: Rech RH, Gudelsky GA, eds. 5-HT agonists as psychoactive drugs. Ann Arbor, MI: NPP Books, 1988:1988:35-60.
21. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993;54:14-34.
22. Aranow RB, Hudson JI, Pope HG, Grady TA, Laage TA, Bell IR, Cole JO. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 1989;146:911-3.
23. Glue P, Banfield C. Psychiatry, psychopharmacology and P-450s. Hum Psychopharmacol 1996;11:97-114.
24. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull 1994;30:251-9.
25. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-48.
26. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human microsomes. Br J Clin Pharmacol 1992;34:262-5.
27. Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-61.
28. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-9.
29. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-83.
30. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
31. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brisen K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-9.
32. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured clinical interview according to DSM-III-R. New York: American Press, 1990.
33. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-61.
34. Nilsen OG, Dale O, Husebo B. Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. Pharmacol Toxicol 1993;72:286-9.
35. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1081-98.
36. Suchow RF, Cooper TB, Kahn RS. High-performance liquid Chromatographic method for the analysis of plasma m-chlorophenylpiperazine. J Chromatogr A 1996;528:228-34.
37. Howell DC. Multiple comparisons among treatment means. In: Howell DC, ed. Statistical methods for psychology. Boston: Duxbury Press, 1982:289-307.
38. Monteleone P, Gnocchi G, Delrio G. Plasma trazodone concentrations and clinical response in elderly depressed patients: a preliminary study. J Clin Psychopharmacol 1989;9:284-7.
39. Spar JE. Plasma trazodone concentrations in elderly depressed inpatients: cardiac effects and short-term efficacy. J Clin Psychopharmacol 1987;7:406-9.
40. Greenblatt DJ, Friedman H, Burstein ES, Scavone JM, Blyden GT, Ochs HR, Miller LG, Harmatz JS, Shader RI. Trazodone kinetics: effects of age, gender, and obesity. Clin Pharmacol Ther 1987;42: 193-200.
41. Ishida M, Otani K, Kaneko S, Ohkubo T, Osanai T, Yasui N, Mihara K, Higuchi H, Sugawara K. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol 1995; 10:143-6.
42. Mayol RF, Gammens RE, LaBudde JA. Simultaneous determination in plasma of trazodone and its metabolite m-chlorophenylpiperazine using a new HPLC method after single and multiple oral dosing in man [abstract]. J Clin Pharmacol 1984;24:406.
43. Maes M, Meltzer HY. Behavioral and endocrine effects to mCPP, a serotonin agonist, in schizophrenia. Psychiatr Res 1996;64: 147-59.
44. Meltzer HY, Maes M. Pindolol pretreatment blocks stimulation by mCPP of prolactin but not cortisol secretion in normal man. Psychiatry Res 1995;58:89-98.
45. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Ishida M, Mihara K, Kondo T, Sugawara K, Fukushima Y. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995; 17:333-5.
46. Ishida M, Otani K, Mihara K, Yasui N, Kondo T, Osanai T, Ohkubo T, Sugawara K, Kaneko S, Fukushima Y. Steady state plasma kinetics of trazodone and m-chlorophenylpiperazine [abstract]. Neuropsychopharmacology 1994;10[suppl 3, pt 2]:262S.
47. Mihara K, Otani K, Ishida M, Yasui N, Suzuki A, Ohkubo T, Osanai T, Kaneko S, Sugawara K. Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol. Ther Drug Monit 1997;19:43-5.
48. Baumann MH, Mash DC, Staley JK. The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain. Clin Neurosci Neuropathol 1995;6:2150-2.
49. 1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 1993;231:223-9.
50. 2C receptor. Psychopharmacology 1996;126:234-40.
51. Benjamin J, Greenberg BD, Murphy DL. Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects. Psychopharmacology 1996;127:140-9.
52. Aulakh CS, Mazzola-Pomietto P, Hill JC, Murphy DL. Role of various 5-HT receptor subtypes in mediating neuroendocrine effects of 1-(2,5-dimethoxy4-methylphenyl)-2-aminopropane (DOM) in rats. J Pharmacol Exp Ther 1994;271:143-8.
53. 2C receptors, respectively. Neuropsychopharmacology 1995;13:1-8.
54. Sills MA, Lucki I, Frazer A. Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated administration of either 5-MeODMT or mCPP. Life Sci 1985;36:2463-9.
55. Kennedy AJ, Gibson EL, O'Connell MT, Curzon G. Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioral responses to mCPP. Psychopharmacology 1993;113: 262-8.
56. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TCG, Zussman BD. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-87.